MIT Project ALPHA Aiming to Give Early Biopharma Investors Better Odds

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Automation and Miniaturization Are Upon Us: Gritstone’s Mission to Make Personalized Medicines
HBV Curative Treatments Gear Up in the Clinic, as HCV Combos Help to Guide the Way
Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped
New Gene-Editing Candidates Target Blood Disorders, as Gene Therapies Start to Hit the Market